Cargando…
Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources
BACKGROUND: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis incidence during IL-17 inhibitor therapy. We describe the worldw...
Autores principales: | Davidson, Linda, van den Reek, Juul M.P.A., Bruno, Mariolina, van Hunsel, Florence, Herings, Ron M.C., Matzaraki, Vasiliki, Boahen, Collins K., Kumar, Vinod, Groenewoud, Hans M.M., van de Veerdonk, Frank L., Netea, Mihai G., de Jong, Elke M.G.J., Kullberg, Bart Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671639/ https://www.ncbi.nlm.nih.gov/pubmed/34950923 http://dx.doi.org/10.1016/j.lanepe.2021.100266 |
Ejemplares similares
-
An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis
por: Rosati, Diletta, et al.
Publicado: (2020) -
Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study
por: van Hal, Tamara W, et al.
Publicado: (2021) -
Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Drug Reactions from the World Health Organization Pharmacovigilance Center
por: DAVIDSON, Linda, et al.
Publicado: (2022) -
Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy
por: Davidson, Linda, et al.
Publicado: (2018) -
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)